In This Week’s Issue:
- Forbes: Are You Just a Number? How New Healthcare Value Frameworks Miss the Point, click here to view the article.
- ICER: Scoping Document for Review of Rheumatoid Arthritis Drugs Posted for Public Comment, click here to view the release.
- Morning Consult: Health Care Payment Is Shifting to Reward Value, but Can Information on Health Care's Value Be Shared?, click here to view the op-ed.
- Video: Dr. Marcia Wilson Discusses the Patient's Role in Quality Measurements, click here to view the video.
- Morning Consult: Value Frameworks Are Expanding For Drugs & Devices, click here to view the article.
- PCORI Awards Nearly $700,000 to 46 Projects Through Pipeline to Proposal Awards, click here to view the press release.
1. Forbes: Are You Just a Number? How New Healthcare Value Frameworks Miss the Point
As healthcare economists Tomas J. Philipson and Jason Shafrin comment in Forbes, “The goal of value frameworks should not be to identify the highest value treatment on average and then restrict access to all other treatments. Rather, value frameworks should be used to promote the optimal matching of patients to existing therapies based on each patient's unique characteristics. What works for one patient may not work for another—this is best understood on a decentralized level, as a patient and his physician typically know what's best for that given patient. Ranking products is not useful when matching products should be the goal.” Click here to view the article.
2. ICER: Scoping Document for Review of Rheumatoid Arthritis Drugs Posted for Public Comment
As detailed in a recent press release, “The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for rheumatoid arthritis...The scoping document will guide development of a report that will serve as the basis for deliberation and discussion at an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) to be held on January 26, 2017.” Click here to view the release.
3. Morning Consult: Health Care Payment Is Shifting to Reward Value, but Can Information on Health Care's Value Be Shared?
In a Morning Consult op-ed Dan Leonard of the National Pharmaceutical Council comments, “The communication of health care information is now more important than ever. The products available to treat conditions, the ways in which health care is organized, delivered and reimbursed, and the available information sources and analytic processes have vastly evolved. Now is the time for communication laws, regulations, guidance, and/or policies to evolve in parallel. Click here to view the op-ed.
4. Video: Dr. Marcia Wilson Discusses the Patient's Role in Quality Measurements
In a recent video posted by the American Journal of Managed Care, Marcia Wilson, PhD, MBA, senior vice president of quality measurement at The National Quality Forum, explains why patient-reported outcomes are important and necessary measures that should be used more, as they give the patient a voice in terms of the quality of care they receive. Click here to view the video.
5. Morning Consult: Value Frameworks Are Expanding For Drugs & Devices
A recent article published in Morning Consult examines the growing number of “value frameworks” to help patients and payers decipher which drugs and devices may be most beneficial – and to provide guidance on appropriate market prices. “There are over a half dozen U.S. value assessment frameworks including the Institute for Clinical and Economic Review (ICER); American Society of Clinical Oncology (ASCO); Memorial Sloan Kettering Cancer Center’s DrugAbacus; the National Comprehensive Cancer Network (NCCN); and a collaboration between the American College of Cardiology and the American Heart Association (ACC-AHA).”
“The controversial CMS Part B drug demonstration includes value-based pricing strategies in Phase 2 that depend on a recognized value framework such as ICER. Thus far ICER has mostly looked at the low-hanging fruit – high cost specialty pharmaceutical therapies – but it’s unlikely to stop there. ICER has already reviewed St. Jude’s CardioMEMS and devices for obesity management. An expansion of medical device assessments could be next… New value frameworks are being developed – such as FasterCures – that take into account the patient perspective are being developed and may hold promise. Many of the current frameworks do not include all the benefits that are important to patients such as quality of life, work productivity, caregiver burden, unmet need and burden of illness.” Click here to view the article.
6. PCORI Awards Nearly $700,000 to 46 Projects Through Pipeline to Proposal Awards
As detailed in a press release last week, “The Patient-Centered Outcomes Research Institute (PCORI) has awarded funds totaling $688,000 for 46 projects through its "Pipeline to Proposal" Awards program. These projects were approved for Tier I awards of up to $15,000 each to develop the capacity for patients, caregivers, and other stakeholders to participate in patient-centered clinical comparative effectiveness (CER) research.” Click here to view the press release.
As healthcare economists Tomas J. Philipson and Jason Shafrin comment in Forbes, “The goal of value frameworks should not be to identify the highest value treatment on average and then restrict access to all other treatments. Rather, value frameworks should be used to promote the optimal matching of patients to existing therapies based on each patient's unique characteristics. What works for one patient may not work for another—this is best understood on a decentralized level, as a patient and his physician typically know what's best for that given patient. Ranking products is not useful when matching products should be the goal.” Click here to view the article.
2. ICER: Scoping Document for Review of Rheumatoid Arthritis Drugs Posted for Public Comment
As detailed in a recent press release, “The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for rheumatoid arthritis...The scoping document will guide development of a report that will serve as the basis for deliberation and discussion at an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) to be held on January 26, 2017.” Click here to view the release.
3. Morning Consult: Health Care Payment Is Shifting to Reward Value, but Can Information on Health Care's Value Be Shared?
In a Morning Consult op-ed Dan Leonard of the National Pharmaceutical Council comments, “The communication of health care information is now more important than ever. The products available to treat conditions, the ways in which health care is organized, delivered and reimbursed, and the available information sources and analytic processes have vastly evolved. Now is the time for communication laws, regulations, guidance, and/or policies to evolve in parallel. Click here to view the op-ed.
4. Video: Dr. Marcia Wilson Discusses the Patient's Role in Quality Measurements
In a recent video posted by the American Journal of Managed Care, Marcia Wilson, PhD, MBA, senior vice president of quality measurement at The National Quality Forum, explains why patient-reported outcomes are important and necessary measures that should be used more, as they give the patient a voice in terms of the quality of care they receive. Click here to view the video.
5. Morning Consult: Value Frameworks Are Expanding For Drugs & Devices
A recent article published in Morning Consult examines the growing number of “value frameworks” to help patients and payers decipher which drugs and devices may be most beneficial – and to provide guidance on appropriate market prices. “There are over a half dozen U.S. value assessment frameworks including the Institute for Clinical and Economic Review (ICER); American Society of Clinical Oncology (ASCO); Memorial Sloan Kettering Cancer Center’s DrugAbacus; the National Comprehensive Cancer Network (NCCN); and a collaboration between the American College of Cardiology and the American Heart Association (ACC-AHA).”
“The controversial CMS Part B drug demonstration includes value-based pricing strategies in Phase 2 that depend on a recognized value framework such as ICER. Thus far ICER has mostly looked at the low-hanging fruit – high cost specialty pharmaceutical therapies – but it’s unlikely to stop there. ICER has already reviewed St. Jude’s CardioMEMS and devices for obesity management. An expansion of medical device assessments could be next… New value frameworks are being developed – such as FasterCures – that take into account the patient perspective are being developed and may hold promise. Many of the current frameworks do not include all the benefits that are important to patients such as quality of life, work productivity, caregiver burden, unmet need and burden of illness.” Click here to view the article.
6. PCORI Awards Nearly $700,000 to 46 Projects Through Pipeline to Proposal Awards
As detailed in a press release last week, “The Patient-Centered Outcomes Research Institute (PCORI) has awarded funds totaling $688,000 for 46 projects through its "Pipeline to Proposal" Awards program. These projects were approved for Tier I awards of up to $15,000 each to develop the capacity for patients, caregivers, and other stakeholders to participate in patient-centered clinical comparative effectiveness (CER) research.” Click here to view the press release.